Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion
In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL! Abstracts discussed: https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions) https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R T-ALL https://ash.confex.com/ash/2023/webprogram/Paper187694.html - Cal-PEG is toxic https://ash.confex.com/ash/2023/webprogram/Paper188064.html - Ponatinib + Blinatumomab https://ash.confex.com/ash/2023/webprogram/Paper187773.html - D-ALBA (Dasatinib + Blinatumomab) https://ash.confex.com/ash/2023/webprogram/Paper189632.html - GIMEMA (Dasatinib or Ponatinib + Blinatumomab)